Syndecan-1:A Quantitative Marker for the Endotheliopathy of Trauma by Gonzalez Rodriguez, Erika et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Syndecan-1
Gonzalez Rodriguez, Erika; Ostrowski, Sisse R.; Cardenas, Jessica C.; Baer, Lisa A.;
Tomasek, Jeffrey S.; Henriksen, Hanne H.; Stensballe, Jakob; Cotton, Bryan A.; Holcomb,
John B.; Johansson, Pär I.; Wade, Charles E.
Published in:
Journal of the American College of Surgeons
DOI:
10.1016/j.jamcollsurg.2017.05.012
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Gonzalez Rodriguez, E., Ostrowski, S. R., Cardenas, J. C., Baer, L. A., Tomasek, J. S., Henriksen, H. H., ...
Wade, C. E. (2017). Syndecan-1: A Quantitative Marker for the Endotheliopathy of Trauma. Journal of the
American College of Surgeons, 225(3), 419-427. https://doi.org/10.1016/j.jamcollsurg.2017.05.012
Download date: 03. Feb. 2020
Syndecan-1: A Quantitative Marker for the
Endotheliopathy of TraumaErika Gonzalez Rodriguez, MD, Sisse R Ostrowski, MD, DMSc, Jessica C Cardenas, PhD, Lisa A Baer, BSc,
Jeffrey S Tomasek, MD, Hanne H Henriksen, BSc, Jakob Stensballe, MD, PhD,
Bryan A Cotton, MD, MPH, FACS, John B Holcomb, MD, FACS, Pa¨r I Johansson, MD, DMSc,
Charles E Wade, PhDBACKGROUND: Endothelial glycocalyx breakdown elicits syndecan-1 shedding and endotheliopathy of trauma
(EoT). We hypothesized that a cutoff syndecan-1 level can identify patients with endothelial
dysfunction who would have poorer outcomes.
STUDY DESIGN: We conducted a prospective observational study. Trauma patients with the highest level of
activation admitted from July 2011 through September 2013 were eligible. We recorded de-
mographics, injury type/severity (Injury Severity Score), physiology and outcomes data, and
quantified syndecan-1 and soluble thrombomodulin from plasma with ELISAs. With receiver
operating characteristic curve analysis, we defined EoTþ as the syndecan-1 cutoff level that
maximized the sum of sensitivity and specificity (Youden index) in predicting 24-hour in-
hospital mortality. We stratified by this cutoff and compared both groups. Factors associ-
ated with 30-day in-hospital mortality were assessed with multivariable logistic regression
(adjusted odds ratios and 95% CIs reported).
RESULTS: From receiver operating characteristic curve analysis (area under the curve¼ 0.71; 95% CI 0.58 to
0.84), we defined EoTþ as syndecan-1 level 40 ng/mL (sensitivity ¼ 0.62, specificity ¼ 0.73).
Of the 410 patients evaluated, 34% (n ¼ 138) were EoTþ patients, who presented with higher
Injury Severity Scores (p < 0.001) and blunt trauma frequency (p¼ 0.016) than EoT patients.
Although EoTþ patients had lower systolic blood pressure (median 119 vs 128 mmHg;
p < 0.001), base excess and hemoglobin were similar between groups. The proportion of
transfused (EoTþ 71.7% vs EoT 36.4%; p < 0.001) and deceased EoTþ patients (EoTþ
24.6% vs EoT 12.1%; p < 0.001) was higher. EoTþ was significantly associated with 30-day
in-hospital mortality (adjusted odds ratio ¼ 2.23; 95% CI 1.22 to 4.04).
CONCLUSIONS: A syndecan-1 level 40 ng/mL identified patients with significantly worse outcomes, despite
admission physiology similar to those without the condition. (J Am Coll Surg 2017;225:
419e427.  2017 The Authors. Published by Elsevier Inc. on behalf of the American
College of Surgeons. This is an open access article under the CC BY-NC-ND license
[http://creativecommons.org/licenses/by-nc-nd/4.0/].)Disclosure Information: Nothing to disclose.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Hemorrhage is the leading cause of early and potentially
preventable mortality in trauma patients, with 58% of
these deaths occurring in the first 3 hours after hospital
admission.1 Hemorrhagic shock is the underlying mecha-
nism responsible for this high mortality rate because it
leads to exsanguination, inflammation, coagulopathy,
endothelial dysfunction, and an increase in vascular
permeability.2,3 The endothelial glycocalyx (EGL) is a
negatively charged complex layer of proteoglycans and
glycoproteins on top of endothelial cells of which synde-
cans and hyaluronic acid are major components. This
structure is responsible, in part, for the maintenance of
vascular permeability.4 Loss of the integrity of the EGL
increases vascular permeability, leading to capillary leak,http://dx.doi.org/10.1016/j.jamcollsurg.2017.05.012
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platelets and leukocytes, which initiates an inflammatory
response and alters coagulation.3,5 Damage and thinning
of the EGL have been linked to the deleterious effects
of reperfusion damage (ie after post-cardiac arrest
syndrome) and to other inflammatory states, such as hy-
perglycemia in diabetes mellitus.6-8 Endothelial glycocalyx
breakdown also disturbs blood flow-induced forces, such
as shear stress and wall tension, due to the essential role
that EGL plays as a mechanosensor.9 Therefore, EGL
breakdown can be the pivotal point where the down-
stream effects of trauma interact and lead to endothelial
dysfunction, coagulopathy, edema, and organ dysfunc-
tion, which ultimately results in poor outcomes.2,10 The
systemic effects of these responses comprise the syndrome
called the “endotheliopathy of trauma” (EoT).11
Clinically, there is not yet a readily available method to
quantify endothelial damage, but previous studies have
shown a strong association between the shedding of
EGL componentsdmainly syndecan-1dand coagulop-
athy, edema, and mortality.2,5,10 Syndecan-1 (a heparan-
sulfate proteoglycan expressed in both endothelial and
epithelial cells) has been widely studied in relation to trau-
matic injury and is currently considered a main marker of
EGL breakdown.2,10,12,13 Thrombomodulin is an anticoag-
ulant protein expressed on the endothelial surface and
plays a role in the activation of the protein C anticoagu-
lant pathway.4,14-16 After trauma, the increase of the
inflammatory cytokines tumor necrosis factor a and
interleukin 6 results in downregulation of thrombomodu-
lin and activation of neutrophils that can cleave thrombo-
modulin, releasing it into the circulation as soluble
thrombomodulin (sTM), a less active form and a
well-known marker of endothelial cell injury.14-17
Hemorrhagic shock induces shedding of syndecan-1,
facilitating the exposure of the injured endothelium to
pro-inflammatory mediators and altering its integrity,
which results in increased permeability.10,18 Recently,
Johansson and colleagues demonstrated an association
between sympathoadrenal activation, inflammation,
coagulopathy, and shedding of syndecan-1.2,3,19,20 Otherstudies have also shown the association between high
circulating levels of syndecan-1 and increased endothelial
permeability, which correlated with higher transfusion
volumes and worse outcomes.10 In addition, the protective
effects of therapies that target EoT and EGL, such as
plasma-based resuscitation, seem to be mediated in part
by the modulation of syndecan-1, as demonstrated by
in vitro studies.5,21,22 Similarly, in a rodent model,
Haywood-Watson and colleagues5 showed that fresh
frozen plasma repairs the EGL, restores endothelial
syndecan-1, and modulates inflammation.
Syndecan-1 seems to be involved in several of the
downstream effects after traumatic injury that lead to
the EoT.3,10,19,23 The aim of this study was to determine
a quantitative index of EoT using circulating levels of
syndecan-1, a biomarker of EGL breakdown. We hypoth-
esized that there is a cutoff level of shed syndecan-1 that
allows the identification of trauma patients with endothe-
lial dysfunction, at risk of progressing into EoT, and who
would have an increased need for blood transfusions and
poorer outcomes.
METHODS
Study design and analysis sample
This prospective observational study was conducted at the
Texas Trauma Institute Memorial at Hermann Hospital
Texas Medical Center, a Level I trauma center, and The
University of Texas Health Science Center at Houston.
Earlier approval was obtained from The University of
Texas Health Science Center at Houston IRB
(HSC-GEN-12-0059). The current article reports addi-
tional analysis of data from 410 patients (14 patients
were excluded because of missing essential laboratory
and clinical data) of the 424 patients previously reported
by Johansson and colleagues.20 As we limited our patient
data to having no missing values, there are minor differ-
ences between the articles. We included adult trauma
patients admitted between July 2011 and September
2013 who met criteria for the highest level of trauma
team activation. Consent was obtained from the patient
or a legally authorized representative within 72 hours of
admission. We obtained a waiver of consent for those
patients discharged or who died within 24 hours of
admission. We excluded cases where patients were
younger than 18 years, pregnant, prisoners, and enrolled
in other studies; patients who declined to give consent
(their blood samples destroyed); and those from whom
we could not obtain an initial blood draw. On emergency
department (ED) arrival, 20 mL of blood was obtained,
then transferred into Vacutainer tubes containing 3.2%
citrate, and inverted to ensure proper anticoagulation.
Assessed for eligibility (n=560)
Excluded (n=150)
Burn trauma (n=56)
Missing essential data or 
syndecan-1 (n=92)
Non-trauma (n=2)
EoT- (n=272)
Patients included (n=410)
EoT+ (n= 138)
Figure 1. CONSORT (Consolidated Standards of Reporting Trials)-
like diagram showing the selection process used to identify
trauma patients for inclusion in the study. EoT, endotheliopathy of
trauma.
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patients. Only patients suffering from blunt or pene-
trating trauma with available data on Injury Severity Score
(ISS) and syndecan-1 levels were included in the analysis.
This resulted in the exclusion of 150 patients (Fig. 1). The
excluded patients did not differ significantly from the
population of this study: median age was 40 years (inter-
quartile range [IQR] 27 to 50 years), 78% were male, and
in-hospital mortality was 14.8%. Designated study
personnel prospectively collected patient demographics,
vital signs, standard laboratory values, transfusions data,
weighted revised trauma scores, and mechanisms and
severity of injuries at the time of admission. Outcomes
and complications data were obtained from medical
records.
ELISAs
Plasma obtained at baseline (on admission to the ED) was
used to quantify levels of syndecan-1 using commercially
available immunoassays (syndecan-1; Diaclone SAS;
lower limit of detection 4.94 ng/mL), and sTM as a
marker of endothelial cell injury (sTM; Nordic Biosite;
lower limit of detection 0.31 ng/mL) according to manu-
facturer recommendations.
Statistical analysis
Summary statistics were used to describe continuous
variables (medians and IQRs reported throughout) and
categorical data were presented as frequency and percent-
age. Comparisons between the EoT and EoTþ study
groups for continuous variables were assessed using
2-sample t-tests for normally distributed data and
Mann-Whitney U or Kruskal-Wallis tests in case of
non-normally distributed data. Chi-square tests were
used for comparisons between categorical variables. Sta-
tistical significance was set at the p < 0.05 level. The
correlation between syndecan-1 and sTM was explored
with Spearman’s rank correlation coefficient. The
primary EoT biomarker of interest was on-admission
syndecan-1 levels. We used receiver operating character-
istic (ROC) curve analysis with the Youden index to
determine the cutoff value of syndecan-1 that maximized
the sum of sensitivity and specificity in predicting
24-hour in-hospital mortality. We chose mortality dur-
ing the first 24 hours (counting from ED admission)
as the end point for this ROC analysis; as has been
reported in several studies,1,24,25 most deaths in trauma
patients occur during this time window. Therefore, it
is during these first 24 hours that interventions that
target the EoT and have the potential to improve out-
comes should be implemented. We validated the
obtained ROC curve with 3-fold cross validation. Theinferred cutoff value was then used to classify patients
into an EoTþ group based on a syndecan-1 level
40 ng/mL or an EoT group those with levels below
this cutoff.
Our main outcome was 30-day in-hospital mortality.
Purposeful selection of covariates26,27 was used to
construct a multivariable logistic regression model for
factors associated with 30-day in-hospital mortality. We
predefined clinically relevant variables in hemorrhagic
shock and trauma that are usually collected within 30 mi-
nutes of hospital arrival, such as laboratory parameters,
vital signs, mechanism and severity of injury, as well as
our biomarker of interest EoTþ (as defined). After the
model building approach mentioned,26,27 only variables
with a p value < 0.2 in the univariate analysis were
included in the preliminary model: age, EoTþ
(as defined), ISS, blunt mechanism, ED systolic blood
pressure, platelet count, sex, and base excess. After pur-
poseful selection of covariates, we obtained 4 variables
of significance, age, ISS, EoTþ, and ED systolic blood
pressure, which were entered into a multivariable logistic
regression model for factors associated with 30-day
in-hospital mortality. We also controlled for base excess
because this variable, despite lacking statistical signifi-
cance, had a significant effect in the presence of other
variables. Results are presented as adjusted odds ratios
with 95% CIs and p values for all covariates in the final
model. The presented adjusted odds ratios are interpreted
as changes in the odds per unit in the predictor for the
continuous variables (age, ISS, ED systolic blood pres-
sure, and base excess) after adjusting for the other
variables in the model. All statistical analysis was
conducted with commercially available software, STATA,
version 13.0 (Stata Corp).
422 Gonzalez Rodriguez et al Quantification of the Endotheliopathy of Trauma J Am Coll SurgRESULTS
Syndecan-1 and sTM levels were measured from samples
collected on ED arrival from 410 patients. Overall,
76.8% of these patients were male, with a median age of
40 years (IQR 27 to 55 years) (Table 1). Blunt trauma
was the predominant mechanism of injury (71.5%) and
patients were moderately injured (median ISS 17; IQR 9
to 26). Most patients were normotensive on ED admission
with median systolic blood pressure of 124 mmHg (IQR
107 to 142 mmHg), slightly acidotic with a median pH
of 7.32 (IQR 7.25 to 7.37), and had ED hemoglobin
(median 13.1 g/dL) and platelet count levels (median
221  109/L) within normal ranges. The overall 30-day
in-hospital mortality rate was 16.3% (Table 1), with nearly
two-thirds of the deaths occurring within the 24 hours after
hospital admission. Death on the first day of hospital
admission was due to head injury (n¼ 24 [61.5%]), hem-
orrhage (n ¼ 11 [28.2%]), and other causes, including
cardiac arrest and respiratory failure (n ¼ 4 [10.3%]).Defining the endotheliopathy of trauma
Our primary biomarker of interest was circulating levels
of syndecan-1 measured in blood samples collected on
arrival. Initially, we explored differences in transfusion
and 30-day in-hospital mortality rates across quartiles.
We found that compared with the rest, patients with
syndecan-1 levels in the upper quartile (60 ng/mL)
had the highest rates of blood transfusions and 30-day
in-hospital mortality, 73.8% and 26.2%, respectively
(both p< 0.01). In addition, syndecan-1 levels of nonsur-
vivors were significantly higher than those of survivors
(median syndecan-1 level in survivors 24.7 ng/mL vs me-
dian syndecan-1 level in nonsurvivors 40.4 ng/mL;
p ¼ 0.01). At the cutoff level 60 ng/mL, the sensitivity
and specificity to identify 24-hour in-hospital mortality
were only 47.0% and 76.5%, respectively. To better iden-
tify a cutoff level of syndecan-1 to define EoTþ, we con-
structed an ROC analysis with the Youden index (J) and
24-hour in-hospital mortality as the outcomes variable
(area under the curve ¼ 0.71; 95% CI 0.58 to 0.84;
Fig. 2). With the Youden index, we determined our cutoff
level (syndecan-1 40 ng/mL) as the level of syndecan-1
that maximized the sum of sensitivity and specificity in
predicting 24-hour in-hospital mortality (J ¼ 0.35, sensi-
tivity at cutoff ¼ 0.62, specificity at cutoff ¼ 0.73). We
validated the fitted ROC curve analysis with 3-fold cross
validation. Syndecan-1 was predictive of 24-hour
in-hospital mortality in both the fitted model and in the
cross-validated model (mean cross-validated area under
the curve ¼ 0.67; IQR 0.59 to 0.74) corroborating our
findings.After stratification by the optimal cutoff, patients
defined as EoTþ (n ¼ 138; syndecan-1 40 ng/mL)
were compared with patients EoT (n ¼ 272; syndecan-
1 <40 ng/mL). Median syndecan-1 concentration was
more than 6 times higher in EoTþ than in EoT patients
(EoTþ median 108 ng/mL vs EoT median 17 ng/mL; p
< 0.001). Although there were no differences in age or sex
between groups, type of trauma, injury severity, and
anatomical region of injury did differ significantly.
EoTþ patients were more likely to suffer from blunt and
chest trauma and were significantly more injured (EoTþ
ISS median 21 vs EoT ISS median 16) than EoT
patients (all p < 0.05). A detailed summary of median
age, sex, blunt trauma, traumatic brain injury (Abbreviated
Injury Scale Head >2), and chest trauma (Abbreviated
Injury Scale Chest >2) proportions in both groups can
be found in Table 1. When comparing vital signs and
admission physiology between groups, we found that me-
dian ED systolic blood pressure was lower in EoTþ pa-
tients, but not in the hypotensive range. Hemoglobin
and platelet median counts fell into normal ranges; howev-
er, median platelet count was significantly lower in EoTþ
patients (Table 1).
Glycocalyx shedding and endothelial disruption
Soluble thrombomodulin levels in patients EoTþ were
nearly 1.5 times higher (median 6.7 ng/mL) than those
in the EoT group (4.7 ng/mL) (p < 0.001). There
was a positive moderate correlation between syndecan-
1 and sTM levels (Spearman’s r correlation
coefficient ¼ 0.50; 95% CI 0.42 to 0.56).
Transfusions and outcomes
Endotheliopathy of trauma-positive patients had worse
outcomes than EoT patients did. Most patients
(71.7%) in the EoTþ group needed blood transfusions
and required 4 times more units of blood products in
the initial 24 hours than EoT patients (Table 2).
When comparing hospital length of stay, patients without
the syndrome (EoT) had nearly 2 times more hospital-
free days than those in the EoTþ group (median 23 days;
IQR 10 to 28 days and median 13 days; IQR 0 to 25
days, respectively). Similarly, median ICU-free days and
ventilator-free days were also significantly lower in the
EoTþ group than those in the syndrome-free group,
EoT (all p < 0.0001).
When we evaluated 30-day in-hospital mortality, we
found a higher rate of mortality in EoTþ patients than
in EoT patients (Table 2). We constructed a multivari-
able logistic regression model with 5 covariates (EoTþ,
base excess, ISS, ED systolic blood pressure, and age) to
evaluate factors associated with 30-day in-hospital
Table 1. Patient Characteristics, Mechanism and Severity of Injury, Admission Physiology, Endothelial Biomarkers, and
Subgroup Comparisons in 410 Patients Admitted to a Level I Trauma Center
Variable All patients EoT* EoTþy p Value
Demographic
n 410 272 138
Age, y, median (IQR) 40 (27 to 55) 39 (27 to 55) 41 (27 to 55) 0.86
Sex, n (%) 0.61
Female 95 (23.2) 61 (22.4) 34 (24.6)
Male 315 (76.8) 211 (77.6) 104 (75.4)
Injury type and severity
Blunt trauma, n (%) 293 (71.5) 184 (67.6) 109 (79.0) 0.016
Injury Severity Score, median (IQR) 17 (9 to 26) 16 (9 to 25) 21 (10 to 30) <0.001
AIS head 3, n (%) 179 (43.7) 120 (44.1) 59 (42.8) 0.79
AIS chest >2, n (%) 134 (32.7) 71 (26.1) 63 (45.7) <0.001
Admission physiology and biochemistry, median (IQR)
Systolic blood pressure, mmHg 124 (107 to 142) 128 (110 to 145) 119 (91 to 140) <0.001
Heart rate, beats/min 92 (78 to 109) 92 (78 to 110) 92 (79 to 109) 0.99
Base excess, mEq/L 3 (6 to 1) 2 (5 to 1) 3 (7 to 1) 0.13
Platelet count, 109/L 221 (182 to 270) 225 (190 to 272) 211 (162 to 262) 0.005
Hemoglobin, g/dL 13.1 (11.7 to 14.4) 13.2 (11.9 to 14.4) 13 (11.2 to 14.5) 0.37
Glasgow Coma Scale score 11 (3 to 15) 12 (3 to 15) 7 (3 to 15) 0.43
Revised trauma score 6.2 (4.09 to 7.84) 6.9 (4.09 to 7.84) 6 (4.09 to 7.84) 0.044
Biomarker, ng/mL, median (IQR)
Syndecan-1 13 (26 to 60) 17 (10 to 26) 108 (60 to 227)
Soluble thrombomodulin 5.2 (3.8 to 7.2) 4.7 (3.5 to 6.1) 6.7 (5.4 to 9.4) <0.001
Table includes data of 410 patients from the sample population presented previously by Johansson and colleagues.20
*Syndecan-1 <40 ng/mL.
ySyndecan-1 40 ng/mL.
AIS, Abbreviated Injury Scale; EoT, endotheliopathy of trauma; IQR, interquartile range.
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included this variable in the fitted model because it had
a significant effect in the presence of other variables.
While controlling for these variables, we found that
EoTþ was significantly associated with an increased likeli-
hood of 30-day in-hospital mortality (adjusted odds
ratio ¼ 2.23; 95% CI 1.22 to 4.04). Other covariates
associated with an increase in likelihood of 30-day
in-hospital mortality were well-known predictors of
mortality, that is, age, ISS, and ED systolic blood pressure
(Table 3).DISCUSSION
Endotheliopathy of trauma is a term proposed by
Holcomb and Pati11 in an attempt to characterize a
syndrome that arises after injury, probably prompted by
EGL breakdown. Likely, this pivotal event triggers the
downstream responses that lead to systemic effects, such
as coagulopathy, edema, organ-barrier dysfunction, and
endothelial dysfunction. In this study, we demonstrated
that syndecan-1 has a role not only as biomarker ofEGL breakdown, but also as quantitative index for
EoT.3,10,11,13 A syndecan-1 concentration 40 ng/mL
identified a group of patients with endothelial dysfunction
(EoT) in the absence of clinically significant differences in
admission physiology. Interestingly, like the results of pre-
vious studies,1,24 24-hour in-hospital mortality in our
population was predominantly due to head injury, indi-
cating that the observations reported in this study are
generalizable to the trauma population, and not confined
to patients suffering from severe hemorrhage.
To our knowledge, we are the first to report the use
of syndecan-1 as a quantitative index of EoT, and the
results presented in this article support its potential
use as an early biomarker for EoT, especially given
the lack of clinically significant differences in admission
physiology between EoTþ and EoT patients. Clinical
studies have demonstrated elevated levels of syndecan-1
and sTM (markers of EGL breakdown and endothelial
damage, respectively) in relation to trauma-induced
coagulopathy.2,3,14-17 Soluble thrombomodulin is also
independently associated with increased 7-day and
28-day mortality in trauma patients,20 and a higher
Figure 2. Receiver operating characteristic curve analysis and
identification of the optimal cutoff with the Youden index (J) for
syndecan-1 as predictor of 24-hour in-hospital mortality in 410
trauma patients. Patients were defined as having the endotheliop-
athy of trauma (EoTþ) based on a syndecan-1 level 40 ng/mL
selected with the Youden index (J ¼ 0.35) as the cutoff value that
maximized the sum of sensitivity and specificity in predicting 24-
hour in-hospital mortality. The point that corresponds to the cutoff
for the upper quartile of syndecan-1 levels (60 ng/mL) is also
represented here. AUC, area under the curve.
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We explored the correlation between syndecan-1 and
sTM levels in this population and found that, although
significant, the strength of the correlation between
these 2 biomarkers was only moderate. We can specu-
late that this is because, on admission, endothelial cell
damage as evidenced by levels of sTM has not yet
occurred.
The observed increased need for transfusion and higher
mortality in the EoTþ group despite similar admission
physiology among groups is important because this can
reflect initial physiologic deterioration derived from
EGL breakdown as demonstrated by syndecan-1 shed-
ding. At this very early stage, there has not been adequate
time to develop detectable physiologic derangements, but
over time, the downstream effects of the original insult
result in deterioration that could trigger an increased
need for transfusion. Endothelial glycocalyx breakdown
and syndecan-1 shedding triggers neurohormonal overac-
tivation, coagulopathy, endothelial dysfunction, and
increased permeability.2,11,19,24,29 These systemic effects
are potential therapeutic targets, which has prompted
the study of interventions ranging from b-blockers to
modulate the catecholamine surge to plasma to repairthe endothelium.29-34 Therapies such as plasma-based
resuscitation seem to re-establish syndecan-1 on the cell
surface and reduce shedding, while also decreasing
endothelial hyperpermeability and modulating inflamma-
tion.5,13,29,32,35,36 In a mice model, Ban and colleagues21
demonstrated that syndecan-1 mediates the protective
effect that plasma has on intestinal epithelium after hem-
orrhagic shock. In this study, we intended to define clearly
what EoT is clinically by establishing a cutoff. Johansson
and colleagues20 recently showed that syndecan-1, but not
sTM or sE-selectin (biomarkers of endothelial cell damage
and activation, respectively) predicted <24-hour mortal-
ity in trauma patients. We show here that not only is
EoTþ independently associated with 30-day in-hospital
mortality, but EoTþ also identifies a group of patients
with poorer clinical outcomes despite similar admission
physiology among EoTþ and EoT patients. Even
though a sensitivity of 62.0% would result in a number
of false positives, in acute settings such as trauma and
hemorrhagic shock, where most deaths occurred on the
first day of hospital arrival (and >25% within 1 hour of
hospital arrival),24 the benefits of interventions that could
improve outcomes outweigh the risks. A quantitative
marker of EoT provides an objective measure of EGL
breakdown and endothelial damage, and could be used
to assess the progression of EoT. Having indices of EoT
would increase the clinician’s index of suspicion, resulting
in closer surveillance and monitoring of patients. More
importantly, such a quantitative index helps to pave the
way for studies that focus on investigating strategies for
early clinical screening of EoT (in the ED or even the pre-
hospital setting) and timely appropriate interventions that
attempt endothelial repair.2,10,19,20 Syndecan-1 can be used
as a confirmatory marker, but currently its use as an early
screening tool for EoT is less practical because it requires
ELISA assays that are time consuming, so by the time re-
sults are available they are no longer relevant. Therefore,
techniques and studies that focus on the acute clinical
identification of EoT are needed. Previous work at our
laboratory demonstrated that trauma patients with low
plasmatic oncotic pressure (plasma colloid-osmotic pres-
sure) had higher plasma levels of syndecan-1 and other
glycocalyx components compared with those with normal
levels of plasma colloid-osmotic pressure.10,37 Additional
in vitro experiments also showed an association between
shedding of syndecan-1, higher levels of catecholamines,
and increased permeability in these subjects.10,36 These
findings support the hypothesis that the alteration of
capillary Starling’s forces reflects EGL disruption and
endothelial dysfunction that allow the translocation of
proteins from the intravascular compartment to the inter-
stitial space.37,38
Table 2. Blood Products and Crystalloid Use, Outcomes, and Mortality Comparisons Between Endotheliopathy of Trauma-
Positive and Endotheliopathy of Trauma-Negative Patients
Variable Total EoT* EoTþy p Value
n 410 272 138
Transfusion
Transfused, n (%) 198 (48.3) 99 (36.4) 99 (71.7) <0.001
RBC, U, median (IQR) 0 (0e2) 0 (0e1) 2 (0e6) <0.001
Plasma, U, median (IQR) 0 (0e2) 0 (0e1) 2 (0e6) <0.001
Platelets, U, median (IQR) 0 (0) 0 (0) 0 (0e2) <0.001
24-h total blood,z U, median (IQR) 0 (0e6) 0 (0e2) 4 (0e16) <0.001
24-h total crystalloid volume, mL, median (IQR) 1,600 (0e3,700) 0 (0e2,600) 3,100 (300e5,800) <0.001
Outcomes
Hospital-free days, median (IQR) 21 (4e27) 23 (10e28) 13 (0e25) <0.001
ICU-free days, median (IQR) 28 (16e30) 28 (21e30) 23 (0e29) <0.001
Ventilator-free days, median (IQR) 29 (20e30) 29 (26e30) 28 (0e30) <0.001
24-h mortality, n (%) 39 (9.5) 16 (5.9) 23 (16.7) 0.001
30-d in-hospital mortality, n (%) 67 (16.3) 33 (12.1) 34 (24.6) 0.001
Table includes data of 410 patients from the sample population presented previously by Johansson and colleagues.20
*Syndecan-1 <40 ng/mL.
ySyndecan-1 40 ng/mL.
zTotal units of blood products (RBC, plasma, and platelet units).
EoT, endotheliopathy of trauma; IQR, interquartile range.
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products, the rates of early (within the first 24 hours of hos-
pital arrival) and late (at 30 days of hospital arrival) mor-
tality in the EoTþ group were significantly higher than
in the EoT group. This difference in mortality could
be due to EoTþ patients being more injured, as indicated
by higher ISS. However, endothelial dysfunction could
have been a contributing factor because a higher propor-
tion of patients in the EoTþ group presented with Abbre-
viated Injury Scale Chest scores >2, implicating more
endothelial damage (the lungs represent 7% of endothelial
surface area in the body39), and consequently an increased
risk of EoT.40 A study by Wright and colleagues40 demon-
strated that hemodynamically stable patients that pre-
sented with pulmonary contusion on initial chest x-ray
had a higher prevalence of coagulopathy that probably
ensued from endothelial injury; this finding was also asso-
ciated with a higher mortality rate in these patients. As
demonstrated by Johansson and colleagues2 andOstrowskiTable 3. Multivariable Logistic Regression Model of Variables
Patients Admitted to a Level I Trauma Center
Variable A
Endotheliopathy of trauma-positive
Age, 1 y
Injury Severity Score, 1 point
Arrival systolic blood pressure, 1 mmHg
Base excess, 1 mEq/L
*Adjusted odds ratios are interpreted as changes in the odds per unit in the predictor, f
Age, Injury Severity Score, arrival systolic blood pressure, and base excess were analand colleagues,3 endogenous heparinization can ensue
from EGL breakdown and contribute to trauma-induced
coagulopathy. Although in this study we did not assess
the relationship between high syndecan-1 levels and
altered coagulation parameters, in a recent study our col-
laborators investigated the association between endotheli-
opathy (elevated syndecan-1 and vascular endothelial
cadherin levels), sympathoadrenal activation (elevated
epinephrine levels), and coagulopathy (both hypo- and hy-
percoagulable states) on rapid thromboelastography.41
High epinephrine, syndecan-1, and vascular endothelial
cadherin levels, as well as other clinical parameters, were
independent predictors of hypocoagulopathy, as measured
by rapid thromboelastography. Additionally, other
markers indicative of endothelial activation (circulating
E-selectin), as well as transfusion of plasma in the preho-
spital setting, showed an association with parameters of hy-
percoagulability on rapid thromboelastography. These
findings support the close interplay among EGL,Associated with 30-Day In-Hospital Mortality in 407 Trauma
djusted odds ratio (95% CI)* p Value
2.23 (1.22e4.04) 0.009
1.04 (1.03e1.05) <0.001
1.04 (1.01e1.07) 0.01
1.01 (1.00e1.02) 0.01
0.96 (0.91e1.02) 0.27
or these continuous variables, after adjusting for the other variables in themodel.
yzed in the model as continuous variables.
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ported previously in several studies, but more importantly,
establish an association between coagulopathy measured
by rapid thromboelastography, sympathoadrenal activity,
and endothelial dysfunction in trauma patients.3,16,19,20,42
Our study has several limitations. The single-center
design and relatively small sample size are most notable.
Additionally, because this study was observational, it
cannot provide insight into cause and effect mechanisms,
but simply points toward associations that require addi-
tional study. Because there is no definitive quantitative
marker of EoT, and several mechanisms (some yet to be
identified) are expected to be involved in this syndrome,
using only syndecan-1 and sTM as quantitative markers
of EoT represents a limitation in and of itself. However,
both are well-described biomarkers of EGL and endothe-
lial cell injury, and several studies have demonstrated the
role of syndecan-1 in endothelial damage and disruption,
and the succeeding downstream effects.2,3,10,29,31
CONCLUSIONS
EoT as defined (syndecan-1 level 40 ng/mL) is a
syndrome associated with an increased requirement for
transfusion of blood products, longer hospital stay, and
lower survival rate in the absence of clinically significant
differences in admission physiology. The prompt identifi-
cation of this population is important to develop clinical
studies that allow early diagnosis and treatment of EoT,
that is, patients in need of endothelial repair. Clinically,
timely interventions aimed at protecting and repairing
the endothelium and its EGL could attenuate or prevent
traumatic endotheliopathy and potentially improve out-
comes, but this warrants additional research.
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